Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncopeptides AB ( (SE:ONCO) ) has provided an update.
Oncopeptides AB, a Stockholm-listed biotech focused on targeted therapies for hard-to-treat cancers, develops oncology drugs using its proprietary PDC and SPiKE platforms and is commercializing its lead product in Europe with additional regional partnerships. The company maintains a relatively small but international operational footprint, reflecting a focused growth strategy in niche oncology markets.
The company announced it will publish its first-quarter 2026 report on May 13 at 08:00 CET and will host a webcast and teleconference presentation with CEO Sofia Heigis and CFO Henrik Bergentoft at 09:00 CET the same day. The scheduled Q1 disclosure and interactive Q&A underline Oncopeptides’ efforts to maintain transparent communication with investors, analysts and media at a time when execution on commercialization and pipeline progress remain central to its value proposition.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers. It leverages its proprietary Peptide Drug Conjugate (PDC) and SPiKE technology platforms to develop compounds that selectively deliver cytotoxic agents into cancer cells. Its flagship oncology drug is being commercialized in Europe, supported by partnership agreements in South Korea, the Middle East, Africa and other markets, and the company operates with about 80 employees across Sweden, Germany, Austria, Spain and Italy while being listed on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 3,083,177
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK492.6M
See more data about ONCO stock on TipRanks’ Stock Analysis page.